298 related articles for article (PubMed ID: 18027225)
1. Analysis strategies for adaptive designs with multiple endpoints.
Chang M; Chow SC
J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
[TBL] [Abstract][Full Text] [Related]
2. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
4. Statistical considerations for the next generation of clinical trials.
Wu W; Shi Q; Sargent DJ
Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
[TBL] [Abstract][Full Text] [Related]
5. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
6. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
7. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
[TBL] [Abstract][Full Text] [Related]
8. How to deal with multiple endpoints in clinical trials.
Neuhäuser M
Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
[TBL] [Abstract][Full Text] [Related]
9. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
Wang J
J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
[TBL] [Abstract][Full Text] [Related]
10. Adaptive design method based on sum of p-values.
Chang M
Stat Med; 2007 Jun; 26(14):2772-84. PubMed ID: 17133651
[TBL] [Abstract][Full Text] [Related]
11. Analysis of trichotomous pharmaceutical endpoints.
Berger VW; Durkalski VL
J Biopharm Stat; 2005; 15(4):739-45. PubMed ID: 16022176
[TBL] [Abstract][Full Text] [Related]
12. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
13. Gatekeeping testing via adaptive alpha allocation.
Li JD; Mehrotra DV
Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
[TBL] [Abstract][Full Text] [Related]
14. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
15. Design and analysis of crossover trials for absorbing binary endpoints.
Nason M; Follmann D
Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
[TBL] [Abstract][Full Text] [Related]
16. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
Jörgens S; Wassmer G; König F; Posch M
Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
[TBL] [Abstract][Full Text] [Related]
17. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
[No Abstract] [Full Text] [Related]
18. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant.
Dmitrienko A; Offen WW; Westfall PH
Stat Med; 2003 Aug; 22(15):2387-400. PubMed ID: 12872297
[TBL] [Abstract][Full Text] [Related]
19. Adaptive seamless designs: selection and prospective testing of hypotheses.
Jennison C; Turnbull BW
J Biopharm Stat; 2007; 17(6):1135-61. PubMed ID: 18027222
[TBL] [Abstract][Full Text] [Related]
20. A reviewer's perspective on multiple endpoint issues in clinical trials.
Huque MF; Sankoh AJ
J Biopharm Stat; 1997 Nov; 7(4):545-64. PubMed ID: 9358328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
